米纳瑞斯制药
MLYS
20.30
-1.34
-6.19%
米纳瑞斯制药
US · MLYS
#2760 按市值排名
上市于 2023
20.30
-1.34
-6.19%
实时 - 追踪5344个代码 - 心跳于18秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了1家。
- 机构持股总比例下降了0.6个百分点。
机构持股
- 机构持股比例
- 114.37% -0.62pp
- 机构数量
- 284 -1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund48.52%
VC/PE Fund31.73%
Hedge Fund27.76%
Public Company3.99%
Private Company1.10%
Sovereign Wealth Fund0.93%
Individual/Insider0.59%
Government Pension Fund0.33%
主要股东 截至 2026-09-22
Catalys Pacific
8.82% · 7.80M 股
RA Capital Management, L.P.
8.70% · 7.69M 股
BlackRock
6.66% · 5.89M 股
Samsara BioCapital LLC
6.64% · 5.87M 股
FMR
5.10% · 4.51M 股
State Street Global Advisors
4.68% · 4.14M 股
Deerfield Management Company, L.P.
4.48% · 3.96M 股
Vanguard Capital Management, LLC
3.63% · 3.21M 股
Laurion Capital Management LP
2.83% · 2.51M 股
T. Rowe Price Group, Inc.
2.56% · 2.26M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 4次买入 · 44次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Jon Congleton | Chief Executive Officer | 0.52% |
| Eric Warren | Chief Commercial Officer | 0.04% |
| David Rodman | Chief Medical Officer | 0.01% |
| Daphne Karydas | Director | 0.01% |
| Adam Levy | CFO, Chief Business Officer & Secretary | 0.00% |
| Glenn Sblendorio | Director | -- |
| Srinivas Akkaraju | Independent Director | -- |
| RA Capital Management, L.P. | -- | -- |
| James Ferguson | Chief Medical Officer | -- |
| Alexander Gold | Director | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-29 | Jon Congleton | Chief Executive Officer | Automatic Disposition | -75,000 | $25.46 |
| 2026-09-21 | Catalys Pacific | -- | Open Market Disposition | -104,320 | $28.81 |
| 2026-09-20 | Eric Warren | Chief Commercial Officer | Derivative Exercise and Sale | -7,438 | $13.24–28.12 |
| 2026-09-16 | David Rodman | Chief Medical Officer | Intent to Sell (Form 144) | -417 | $27.95 |
| 2026-09-14 | Daphne Karydas | Director | Derivative Exercise and Sale | -3,000 | $12.02–28.58 |
| 2026-09-13 | David Rodman | Chief Medical Officer | Intent to Sell (Form 144) | -7,709 | $28.14 |
| 2026-09-08 | David Rodman | Chief Medical Officer | Intent to Sell (Form 144) | -2,171 | $30.87 |
| 2026-08-20 | Eric Warren | Chief Commercial Officer | Derivative Exercise and Sale | -7,437 | $13.24–25.98 |
| 2026-08-16 | David Rodman | Chief Medical Officer | Intent to Sell (Form 144) | -417 | $25.46 |
| 2026-08-12 | David Rodman | Chief Medical Officer | Intent to Sell (Form 144) | -14,056 | $26.48 |
| 2026-08-09 | James Ferguson | Chief Medical Officer | Other Acquisition | +102,400 | -- |
| 2026-08-09 | James Ferguson | Chief Medical Officer | Other Derivative Acquisition | +135,000 | $27.38 |
| 2026-08-09 | David Rodman | Chief Medical Officer | Derivative Exercise and Sale | -2,170 | $16.00–27.09 |
| 2026-07-20 | Eric Warren | Chief Commercial Officer | Derivative Exercise and Sale | -7,438 | $13.24–26.87 |
| 2026-07-16 | David Rodman | Chief Medical Officer | Derivative Exercise and Sale | -416 | $15.44–26.53 |
| 2026-07-14 | David Rodman | Chief Medical Officer | Automatic Disposition | -6,349 | $26.61 |
| 2026-07-12 | David Rodman | Chief Medical Officer | Intent to Sell (Form 144) | -14,058 | $27.58 |
| 2026-07-12 | David Rodman | Chief Medical Officer | Derivative Exercise and Sale | -14,058 | $1.08–27.58 |
| 2026-07-12 | Jon Congleton | Chief Executive Officer | Automatic Disposition | -10,700 | $27.24 |
| 2026-07-08 | David Rodman | Chief Medical Officer | Derivative Exercise and Sale | -2,171 | $16.00–30.30 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:05 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
米纳瑞斯制药 讨论区 0 条评论